Current Research Focus

1. Clinical Outcomes for Peritoneal Dialysis and Home Hemodialysis:

Clinical studies include: Impact on cardiovascular function; improvements in nocturnal dialysis; participation in mega trials such as the NIH-sponsored ACTIVE (A Clinical Trial of Intensive Dialysis) study and the Baxter-sponsored IMPENDIA study; survival rates for Home Hemodialysis; extended criteria kidneys for transplant patients; reduced glucose regimes in Peritoneal Dialysis for diabetic patients and patients with elevated cholesterol and lipid levels.

2. Biomarker Discovery for Home Dialysis:

Patients with chronic kidney disease are at higher risk of cardiovascular disease, including sudden death, coronary artery disease, congestive heart failure, stroke, and peripheral artery disease. Recently, a number of cardiovascular biomarkers have been identified as predictors of outcomes in kidney disease. Other studies focus on the potential diagnostic and prognostic use of new biomarkers and factors affecting kidney disease including changes in gene regulation; changes in intensity of dialysis; innate immunity and uremia.

3. Technical Innovations:

Partnering with the UHN Centre for Global ehealth innovation, the team is involved in usability studies of home dialysis modalities, as well as assessment of patient attitudes in Home Hemodialysis. The goal of this research is to increase the spectrum of patients who can benefit from HHD. Other innovations include how to optimize home dialysis for patients who have disabilities such as deafness and blindness. For Peritoneal Dialysis, studies involve assessing the effectiveness of laparoscopic techniques involving placement, function and maintenance of PD catheters.

4. Integration with Chronic Kidney Disease Care Models:

The focus of this research is identifying patients who would benefit most from suitable modalities. Patient groups include those who come through referral, patients who present with sudden kidney failure, predialysis transplant patients, and patients who come for chronic kidney disease assessment.